Vascular disease in male patients with Fabry disease on hemodialysis: a retrospective cohort study in Argentina
Abstract
Introduction: Vascular events (VE), both cardiovascular (CVD) and cerebrovascular (CVA), are the main cause of death in patients with Fabry disease (FD). The aim of this study was to describe the occurrence of VE in patients with FD and end-stage renal disease (ESRD) on hemodialysis during follow-up. Methods: a retrospective, cohort study was carried out at three centers in Argentina between January 2010 and January 2017. Hemodialysis patients with FD and ESRD were included. Information was collected regarding demographic, clinical and VE aspects. Results: Eight adult (40 ± 4.2 year-old) male patients with ESRD on hemodialysis (mean time on dialysis: 39.1 ± 20.6 months) were included; the mean followup time was 55 ± 12 months. Five patients received enzyme replacement therapy during follow-up. Four patients (50%) had VE during follow-up. In three of them the cardiovascular event was fatal. The mean time from admission to dialysis until the onset of VE was 38 ± 8 months. Conclusion: 50% of the patients with FD and ESRD presented a VE in a mean time of approximately 38 months since their admission to dialysis.
References
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790-6.
Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009;46(8):548-52.
Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC Nephrol. 2014;15:72.
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345(1):9-16.
Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743-9.
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77-86.
Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547-57.
West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20(5):1132-9.
Tøndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129(1):16-21.
Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet. 2016;53(7):495-502.
Rombach SM, van den Bogaard B, de Groot E, Groener JE, Poorthuis BJ, Linthorst GE, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension. 2012;60(4):998-1005.
Loso J, Lund N, Avanesov M, Muschol N, Lezius S, Cordts K, et al. Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy. Front Cardiovasc Med. 2018;5:108.
Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25(3):769-75.
Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61(1):249-55.
O'Donnell CJ1, Elosua R. [Cardiovascular risk factors. Insights from Framingham Heart Study]. Rev Esp Cardiol. 2008;61(3):299-310.
Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag. 2009;5:713-22.
Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30.
Jaurretche S, Antogiovanni N, Perretta F. Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina. Mol Genet Metab Rep. 2017;12:41-43.
Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102-11.
Kosch M, Koch HG, Oliveira JP, Soares C, Bianco F, Breuning F, et al. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int. 2004;66(3):1279-82.
Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21(1):44-52.
